Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Depomed has received a clinical grant from The Michael J Fox Foundation under its Clinical Intervention Awards 2010 program, for the development of a gastric retentive extended-release tablet of levodopa/carbidopa.
Subscribe to our email newsletter
The tablet targets constant blood levels of levodopa compared to current therapy while reducing dosing frequency and maintaining effectiveness in controlling Parkinson’s symptoms.
Depomed said that the two different gastric retentive extended-release tablet formulations that deliver levodopa and carbidopa with different release profiles over 8hr will be administered to Parkinson’s disease patients following a meal.
Depomed president and CEO Carl Pelzel said that they are grateful to The Michael J Fox Foundation for their continued support since they received a preclinical grant from them in July 2008.
"We look forward to working with the Foundation on advancing our early-stage Parkinson’s program that is based on our Acuform drug delivery technology," Pelzel said.